Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 28 Jan 2017 This trial was completed in Belgium, according to European Clinical Trials Database.
- 20 Dec 2016 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
- 20 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.